JP2020515283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515283A5 JP2020515283A5 JP2019556553A JP2019556553A JP2020515283A5 JP 2020515283 A5 JP2020515283 A5 JP 2020515283A5 JP 2019556553 A JP2019556553 A JP 2019556553A JP 2019556553 A JP2019556553 A JP 2019556553A JP 2020515283 A5 JP2020515283 A5 JP 2020515283A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- sequence identity
- amino acids
- contiguous amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 59
- 235000001014 amino acid Nutrition 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 37
- 241000700605 Viruses Species 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 241001217856 Chimpanzee adenovirus Species 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 230000028993 immune response Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439865P | 2016-12-28 | 2016-12-28 | |
| US62/439,865 | 2016-12-28 | ||
| US201762550167P | 2017-08-25 | 2017-08-25 | |
| US62/550,167 | 2017-08-25 | ||
| PCT/US2017/068800 WO2018126060A1 (en) | 2016-12-28 | 2017-12-28 | Influenza vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515283A JP2020515283A (ja) | 2020-05-28 |
| JP2020515283A5 true JP2020515283A5 (OSRAM) | 2021-04-08 |
Family
ID=62710906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556553A Pending JP2020515283A (ja) | 2016-12-28 | 2017-12-28 | インフルエンザワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11111277B2 (OSRAM) |
| EP (1) | EP3562498A4 (OSRAM) |
| JP (1) | JP2020515283A (OSRAM) |
| KR (1) | KR20190129032A (OSRAM) |
| CN (1) | CN111148528A (OSRAM) |
| AU (1) | AU2017386682A1 (OSRAM) |
| BR (1) | BR112019013402A2 (OSRAM) |
| CA (1) | CA3048448A1 (OSRAM) |
| MX (1) | MX2019007924A (OSRAM) |
| WO (1) | WO2018126060A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017386682A1 (en) | 2016-12-28 | 2019-07-25 | Invvax, Inc. | Influenza vaccines |
| KR20220047332A (ko) * | 2019-08-13 | 2022-04-15 | 알티뮨 인크. | 치료제 효과 및 이의 투여 경로 |
| CN110772635B (zh) * | 2019-11-11 | 2023-01-31 | 扬州大学 | 流感病毒小体包被的仿生纳米疫苗及其制备方法 |
| CN120775884A (zh) * | 2024-04-08 | 2025-10-14 | 康希诺(上海)生物研发有限公司 | 一种流感mRNA疫苗及其制备方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1040001A (en) | 1909-03-23 | 1912-10-01 | Bofors Gullspaang Ab | Breech-loading mechanism for artillery-guns. |
| US1017917A (en) | 1910-12-17 | 1912-02-20 | Joseph E Runner | Combination block and tile machine. |
| US1023874A (en) | 1911-10-12 | 1912-04-23 | Thomas J Price | Drinking-fountain. |
| US1042682A (en) | 1912-04-17 | 1912-10-29 | Okey J Jackson | Toy cycle. |
| WO2004031211A2 (en) | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| WO2001000225A1 (en) | 1999-06-29 | 2001-01-04 | Epimmune Inc. | Hla binding peptides and their uses |
| US6740506B2 (en) | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| AU1449499A (en) | 1997-10-31 | 1999-05-24 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
| JP2002507397A (ja) | 1998-03-13 | 2002-03-12 | エピミューン,インコーポレイティド | Hla結合ペプチド及びその使用 |
| US6337186B1 (en) | 1998-06-17 | 2002-01-08 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
| IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| AU785319B2 (en) * | 1999-09-16 | 2007-01-11 | Eisai Inc. | Nucleic acids encoding polyepitope polypeptides |
| CN100412190C (zh) | 2001-03-15 | 2008-08-20 | 复旦大学 | 乙肝病毒全基因组多聚酶嵌合体的组建方法和应用 |
| JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| JP2005500336A (ja) | 2001-07-25 | 2005-01-06 | ニューヨーク・ユニバーシティ | 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用 |
| EP1543039B1 (en) | 2002-08-12 | 2011-07-13 | The Council Of The Queensland Institute Of Medical Research | Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes |
| DK1670914T3 (da) | 2003-10-02 | 2008-05-13 | Basf Se | Fremgangsmåde til sekvensmætnings-mutangenese (SeSaM) |
| GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| EP1819357A4 (en) | 2004-12-09 | 2009-02-25 | Univ Pittsburgh | VACCINES FOR FAST RESPONSE TO A BIRD GRIP PANDEMY |
| BRPI0609362A2 (pt) | 2005-04-11 | 2010-03-30 | Us Gov Health & Human Serv | vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica |
| US20070116717A1 (en) | 2005-08-01 | 2007-05-24 | Shneider Alexander M | Influenza vaccine compositions and methods |
| CA2627105A1 (en) * | 2005-10-26 | 2007-05-03 | Protelix, Inc. | Influenza combinatorial antigen vaccine |
| ATE552846T1 (de) | 2005-12-06 | 2012-04-15 | Yeda Res & Dev | Verbesserter grippeimpfstoff |
| WO2007091387A1 (ja) | 2006-02-07 | 2007-08-16 | Nec Corporation | Hla結合性ペプチド、その前駆体、それをコードするdna断片および組み換えベクター |
| GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
| WO2008039267A2 (en) | 2006-07-21 | 2008-04-03 | Pharmexa Inc. | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
| US8084594B2 (en) * | 2007-07-13 | 2011-12-27 | The United States Of America As Represented By The Secretary Of Agriculture | H2N3 influenza A viruses and methods of use |
| ES2539818T3 (es) | 2007-08-02 | 2015-07-06 | Biondvax Pharmaceuticals Ltd. | Vacunas contra la gripe multiepitópicas multiméricas |
| EP3058954B1 (en) | 2007-08-27 | 2017-03-01 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
| WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
| CN101575608A (zh) * | 2008-05-07 | 2009-11-11 | 中国科学院上海生命科学研究院 | 针对禽流感病毒的重组联合dna疫苗 |
| BRPI0914224A2 (pt) | 2008-06-19 | 2019-09-24 | Variation Biotechnologies Inc | composições e métodos para tratar a gripe |
| EP3009145A1 (en) | 2009-03-30 | 2016-04-20 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
| RU2012107702A (ru) * | 2009-07-31 | 2013-09-10 | Пэксвэкс, Инк. | Векторы на основе аденовирусов |
| JP2013506682A (ja) | 2009-09-30 | 2013-02-28 | セント ルイス ユニバーシティ | 異種亜型インフルエンザt細胞応答を誘発するためのペプチド |
| WO2012082803A2 (en) | 2010-12-13 | 2012-06-21 | Cel-Sci Corporation | Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof |
| CA2828068C (en) | 2011-02-22 | 2019-03-19 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| US10179174B2 (en) * | 2011-05-25 | 2019-01-15 | Cel-Sci Corp. | Method for inducing an immune response and formulations thereof |
| US9205144B2 (en) * | 2011-06-03 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Identification of conserved peptide blocks in homologous polypeptides |
| WO2013093512A2 (en) | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccine - screening method |
| KR101382244B1 (ko) | 2012-03-30 | 2014-04-08 | 재단법인 목암생명공학연구소 | 광범위한 인플루엔자 바이러스의 감염을 방어할 수 있는 t―세포 기반 유니버설 플루 백신 |
| US20140274806A1 (en) * | 2013-03-15 | 2014-09-18 | Synthetic Genomics Vaccines | Influenza virus reassortment |
| JP6550072B2 (ja) | 2014-04-03 | 2019-07-24 | バイオンドバックス ファーマシューティカルズ リミテッド | 多量体マルチエピトープインフルエンザポリペプチドの組成物及びそれらの生成 |
| WO2015157189A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Vaccines and uses thereof |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| EP3452069A4 (en) | 2016-05-03 | 2020-02-12 | The Board of Trustees of the University of Arkansas | Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them |
| AU2017386682A1 (en) | 2016-12-28 | 2019-07-25 | Invvax, Inc. | Influenza vaccines |
| EP3679056A1 (en) | 2017-09-08 | 2020-07-15 | The University of Melbourne | Methods and compositions for preventing influenza infection |
-
2017
- 2017-12-28 AU AU2017386682A patent/AU2017386682A1/en not_active Abandoned
- 2017-12-28 CA CA3048448A patent/CA3048448A1/en not_active Abandoned
- 2017-12-28 JP JP2019556553A patent/JP2020515283A/ja active Pending
- 2017-12-28 KR KR1020197021716A patent/KR20190129032A/ko not_active Withdrawn
- 2017-12-28 WO PCT/US2017/068800 patent/WO2018126060A1/en not_active Ceased
- 2017-12-28 MX MX2019007924A patent/MX2019007924A/es unknown
- 2017-12-28 EP EP17887439.2A patent/EP3562498A4/en not_active Withdrawn
- 2017-12-28 BR BR112019013402-6A patent/BR112019013402A2/pt not_active Application Discontinuation
- 2017-12-28 CN CN201780087550.3A patent/CN111148528A/zh active Pending
- 2017-12-28 US US15/857,436 patent/US11111277B2/en active Active
-
2021
- 2021-07-14 US US17/375,797 patent/US11739127B2/en active Active
-
2023
- 2023-06-30 US US18/344,909 patent/US12234263B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2020515283A5 (OSRAM) | ||
| IL262805B2 (en) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| JP2010500399A5 (OSRAM) | ||
| JP2014502156A5 (OSRAM) | ||
| JP2018504412A5 (OSRAM) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2012500001A5 (OSRAM) | ||
| JP2008530245A5 (OSRAM) | ||
| JP2014508734A5 (OSRAM) | ||
| JP2015522540A5 (OSRAM) | ||
| IL276210B2 (en) | Mers-cov vaccine | |
| NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
| JP2015517489A5 (OSRAM) | ||
| JP2019533722A5 (OSRAM) | ||
| IL316406A (en) | Lipid-modified relaxin B peptide chains and their medical use | |
| JP2010508030A5 (OSRAM) | ||
| RU2009119597A (ru) | Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| CA2593746A1 (en) | Compositions of influenza viral proteins and methods of use thereof | |
| JP2019534709A5 (OSRAM) | ||
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| JP2018501258A5 (OSRAM) | ||
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| AR088028A1 (es) | Proteinas h5, de h5n1 para un uso medicinal |